Zealand Pharma A/S (ZLDPF)

PNK: ZLDPF · Real-Time Price · USD

72.00

-0.28 (-0.39%)

At close: May 01, 2025, 2:17 PM

-0.39% (1D)

Bid	68.52
Market Cap	5.09B
Revenue (ttm)	62.69M
Net Income (ttm)	-1.08B
EPS (ttm)	-2.47
PE Ratio (ttm)	-29.15
Forward PE	n/a
Analyst	n/a

Ask	73.06
Volume	100
Avg. Volume (20D)	673
Open	72.00
Previous Close	72.28
Day's Range	70.33 - 72.00
52-Week Range	57.97 - 141.74
Beta	0.58

About ZLDPF

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hy...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 25, 2013

Employees 335

Stock Exchange PNK

Ticker Symbol ZLDPF

Website https://www.zealandpharma.com

Full Company Profile

News

1 hour ago · zacks.com

Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?

Zealand Pharma AS (ZLDPF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d...

1 week ago · reuters.com

Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or obesit...

2 weeks ago · wsj.com

Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche

The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.

1 month ago · youtube.com

Zealand Pharma's new drug petrelintide will help people lose weight: CEO

Zealand Pharma CEO Adam Steensberg discusses the company's new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.

1 month ago · cnbc.com

Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate. Shares of Zealand Pharma jumped as...

1 month ago · reuters.com

Roche to develop, commercialize obesity drug with Zealand Pharma

Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wedn...

2 months ago · seekingalpha.com

Zealand Pharma A/S (ZLDPF) Q4 2024 Earnings Call Transcript

Zealand Pharma A/S (OTCPK:ZLDPF) Q4 2024 Earnings Conference Call February 20, 2025 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President and Chief Executive Officer Dav...